Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials

贝伐单抗 结直肠癌 危险系数 肿瘤科 医学 置信区间 内科学 子群分析 化疗 无进展生存期 随机对照试验 癌症 荟萃分析
作者
Daniele Rossini,Alessandra Boccaccino,Martina Carullo,Carlotta Antoniotti,Giovanni Dima,Paolo Ciracì,Federica Marmorino,Roberto Moretto,Gianluca Masi,Chiara Cremolini
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:184: 106-116 被引量:20
标识
DOI:10.1016/j.ejca.2023.02.006
摘要

Background Retrospective subgroup analyses of previous trials in the first-line therapy of RAS wt metastatic colorectal cancer (mCRC) suggested a predictive impact of primary tumour side on the efficacy of anti-epidermal growth factor receptor (EGFR) agents. Recently, new head-to-head trials of doublets/bevacizumab versus doublets/anti-EGFR, PARADIGM and CAIRO5 were presented. Patients and methods We searched for phase II and III trials comparing doublet chemotherapy plus an anti-EGFR or bevacizumab as the first-line treatment for RAS wt mCRC patients. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and radical resection rate result in the overall study populations and, according to the primary side, were pooled together in a two-stage analysis with random effects and fixed effect models. The interaction between sidedness and treatment effect was then analysed. Results We identified five trials (PEAK, CALGB/SWOG 80405, FIRE-3, PARADIGM and CAIRO5), including 2739 patients, 77% left- and 23% right-sided. Among patients with left-sided mCRC, the use of anti-EGFRs was associated with higher ORR (74% versus 62%, OR = 1.77 [95% confidence interval {CI} 1.39–2.26–0.88], p < 0.0001), longer OS (hazard ratio [HR] = 0.77 [95% CI 0.68–0.88], p < 0.0001) and not significantly longer PFS (HR = 0.92, p = 0.19). Among patients with right-sided mCRC, the use of bevacizumab was associated with longer PFS (HR = 1.36 [95% CI 1.12–1.65], p = 0.002) and not significantly longer OS (HR = 1.17, p = 0.14). A subgroup analysis confirmed a significant interaction effect between the primary tumour side and treatment arm in terms of ORR (p = 0.02), PFS (p = 0.0004) and OS (p = 0.001). No differences in the radical resection rate were found according to treatment and sidedness. Conclusions Our updated metanalysis corroborates the role of the primary tumour location in the choice of the upfront therapy for RAS wt mCRC patients, leading to strongly recommend anti-EGFRs in left-sided tumours and to prefer bevacizumab in the right-sided.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马甲应助hmwu_test采纳,获得10
1秒前
酷波er应助应樱采纳,获得10
1秒前
盼盼527发布了新的文献求助10
2秒前
2秒前
3秒前
小迪迦奥特曼完成签到,获得积分10
3秒前
凸迩丝儿发布了新的文献求助10
3秒前
彪壮的机器猫完成签到,获得积分10
3秒前
Eric完成签到,获得积分10
3秒前
苏杉杉发布了新的文献求助10
4秒前
寒冷的寒梦完成签到,获得积分10
4秒前
LL发布了新的文献求助10
4秒前
yar应助Amanda采纳,获得10
4秒前
所所应助爱笑发夹采纳,获得10
4秒前
5秒前
6秒前
6秒前
6秒前
wy18567337203完成签到,获得积分10
7秒前
masheng发布了新的文献求助10
7秒前
8秒前
DYQin完成签到,获得积分10
8秒前
8秒前
细腻的海露完成签到 ,获得积分10
9秒前
9秒前
粽子完成签到,获得积分10
10秒前
Fern完成签到 ,获得积分10
10秒前
10秒前
王111完成签到,获得积分10
10秒前
10秒前
berrycute完成签到,获得积分20
11秒前
Rondab应助LL采纳,获得10
11秒前
yar应助DYQin采纳,获得10
11秒前
12秒前
Orange应助苏杉杉采纳,获得10
12秒前
丂枧完成签到 ,获得积分10
12秒前
依小米完成签到 ,获得积分10
12秒前
12秒前
今后应助shifeng采纳,获得10
12秒前
每个人都完成签到,获得积分10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968771
求助须知:如何正确求助?哪些是违规求助? 3513646
关于积分的说明 11169065
捐赠科研通 3249011
什么是DOI,文献DOI怎么找? 1794589
邀请新用户注册赠送积分活动 875236
科研通“疑难数据库(出版商)”最低求助积分说明 804740